GSK plc - 21 Jun 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: 10%+ Owner
Signature: /s/ Victoria A. Whyte
Issuer symbol: LYEL
Transactions as of: 21 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 23 Jun 2021, 18:14:59 UTC
Previous filing: 04 Nov 2022
Next filing: 06 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Conversion of derivative security		+30,253,189			30,253,189	21 Jun 2021	See Footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Series AA Preferred Stock	Conversion of derivative security		-30,253,189	-100%		0	21 Jun 2021	Common Stock	30,253,189		See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").